Terbinafine for the treatment of pedal onychomycosis. A foot closer to the promised land of cured nails?

Shear, Neil H.

doi:10.1001/archderm.131.8.937

Cited by 14 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data about relapses of onychomycosis after treatment with the new systemic antifungals vary in the different studies, with figures ranging from 3 to 20% [4, 5, 6, 7, 8]for terbinafine and from 21 to 27% for itraconazole [9, 10, 11], depending on the follow-up duration. Studies that have followed patients for more than 1 year after the end of therapy usually report a significantly higher relapse rate than short-term studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up

et al. 1998

View full text Add to dashboard Cite

Background: Data about relapses of onychomycosis after treatment with the new systemic antifungals vary among the different studies, with figures ranging from 3 to 20% for terbinafine and from 21 to 27% for itraconazole, depending on the follow-up duration. Objective: To determine the prevalence of relapses of onychomycosis cured by terbinafine compared with that of onychomycosis cured by itraconazole. Methods: We followed up 47 patients whose toenail onychomycosis had been mycologically cured in an open randomized study comparing intermittent itraconazole treatment with continuous terbinafine treatment and intermittent terbinafine therapy. Patients were examined every 3 months for up to 3 years after the end of therapy. At each visit clinical and mycologic (direct microscopy and cultures) evaluations were performed. Results: Eight of the 36 patients (22.2%) who completed the study had a relapse of onychomycosis during the follow-up period, including 2 patients of the terbinafine 250 mg group, 2 patients of the terbinafine 500 mg group and 4 patients in the itraconazole 400 mg group. As the original infection, the relapse was caused in all cases by Trichophyton rubrum. Conclusions: This study shows that 22.2% of patients with onychomycosis successfully treated with systemic antifungals experienced a relapse. The relapse rate increased from 8.3% at month 12 to 19.4% at month 24 and to 22.2% at month 36. Relapses were more common in patients treated with pulse itraconazole (4/11) than in patients treated with continuous (2/12) or intermittent (2/13) terbinafine. Statistical analysis did not reveal any significant difference between relapse rates in the three groups.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, there are only a few studies that evaluate the long-term outcome of patients who have been successfully treated [4, 5, 6, 7, 8, 9]. In particular, there are no studies that compare the prevalence of relapses of onychomycosis cured by terbinafine with that of onychomycosis cured by itraconazole.…”

Section: Introductionmentioning

confidence: 99%

Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up

et al. 1998

View full text Add to dashboard Cite

show abstract

“…It may considerably reduce dexterity and affect working with the hands and fingers, thus interfering with professional activities and becoming a major occupational hazard. 11–21 Nail changes from mycotic infections may provide a portal of entry for secondary bacterial infections. 22 Koebner's phenomenon may be elicited by onychomycosis in patients with psoriasis and lichen planus.…”

Section: Effects Of Onychomycosismentioning

confidence: 99%

“…Onychomycosis clearly fits into the whole realm of visible imperfections that take a psychologic toll on affected persons; these should not be trivialized and ignored. 11–21,32–33 …”

Section: Effects Of Onychomycosismentioning

confidence: 99%

Onychomycosis: clinical perspective

Sehgal

Jain

2000

Int J Dermatology

View full text Add to dashboard Cite

“…2 Prior to the introduction of terbinafine, low cure rates were reported from treatment with griseofulvin for 12-24 months. 3 Our follow up of patients a median of 2 years and 8 months after entry to a 48 week clinical trial of terbinafine 1 has shown at least 80% have remained mycologically cured.…”

Section: Discussionmentioning

confidence: 88%

Long‐term follow up of patients with toenail onychomycosis after treatment with terbinafine

et al. 1998

View full text Add to dashboard Cite

SUMMARYThe long‐term outcome of 111 patients treated with oral terbinafine for toenail onychomycosis with a novel treatment protocol was assessed a median of 138 weeks alter entry into the trial. All but three patients had either one or two 12 week courses of terbinafine 250 mg daily. 01 the 77 evaluable patients, 72.7% were still classified as responders (i.e. negative mycological culture and at least 3 mm olnew unaffected nail growth) on reassessment. The present study shows that a favourable long‐term outcome can be achieved in patients who have been treated with at least one 12 week course of terbinafine.

show abstract

Terbinafine for the treatment of pedal onychomycosis. A foot closer to the promised land of cured nails?

Cited by 14 publications

References 0 publications

Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up

Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up

Onychomycosis: clinical perspective

Long‐term follow up of patients with toenail onychomycosis after treatment with terbinafine

Contact Info

Product

Resources

About